Literature DB >> 15229650

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis.

Jianying Dong1, Jeremy Grunstein, Max Tejada, Frank Peale, Gretchen Frantz, Wei-Ching Liang, Wei Bai, Lanlan Yu, Joe Kowalski, Xiaohuan Liang, Germaine Fuh, Hans-Peter Gerber, Napoleone Ferrara.   

Abstract

We generated VEGF-null fibrosarcomas from VEGF-loxP mouse embryonic fibroblasts to investigate the mechanisms of tumor escape after VEGF inactivation. These cells were found to be tumorigenic and angiogenic in vivo in spite of the absence of tumor-derived VEGF. However, VEGF derived from host stroma was readily detected in the tumor mass and treatment with a newly developed anti-VEGF monoclonal antibody substantially inhibited tumor growth. The functional significance of stroma-derived VEGF indicates that the recruitment of stromal cells is critical for the angiogenic and tumorigenic properties of these cells. Here we identified PDGF AA as the major stromal fibroblast chemotactic factor produced by tumor cells, and demonstrated that disrupting the paracrine PDGFR alpha signaling between tumor cells and stromal fibroblasts by soluble PDGFR alpha-IgG significantly reduced tumor growth. Thus, PDGFR alpha signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. Our findings highlight a novel aspect of PDGFR alpha signaling in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229650      PMCID: PMC514949          DOI: 10.1038/sj.emboj.7600289

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  65 in total

Review 1.  Roles of PDGF in animal development.

Authors:  Renée V Hoch; Philippe Soriano
Journal:  Development       Date:  2003-10       Impact factor: 6.868

2.  Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes.

Authors:  A Siegbahn; A Hammacher; B Westermark; C H Heldin
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

3.  Growth factor requirements of oncogene-transformed NIH 3T3 and BALB/c 3T3 cells cultured in defined media.

Authors:  X Zhan; M Goldfarb
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

4.  Platelet derived growth factor (PDGF) autocrine components in human tumor cell lines.

Authors:  G R Harsh; M T Keating; J A Escobedo; L T Williams
Journal:  J Neurooncol       Date:  1990-02       Impact factor: 4.130

5.  Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains.

Authors:  M P Beckmann; C Betsholtz; C H Heldin; B Westermark; E Di Marco; P P Di Fiore; K C Robbins; S A Aaronson
Journal:  Science       Date:  1988-09-09       Impact factor: 47.728

Review 6.  Structural and functional aspects of platelet-derived growth factor and its role in the pathogenesis of glioblastoma.

Authors:  C Betsholtz; M Nistér; F Rorsman; C H Heldin; B Westermark
Journal:  Mol Chem Neuropathol       Date:  1989-02

7.  Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.

Authors:  Alicia Viloria-Petit; Lucile Miquerol; Joanne L Yu; Marina Gertsenstein; Capucine Sheehan; Linda May; Jack Henkin; Corrinne Lobe; Andras Nagy; Robert S Kerbel; Janusz Rak
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

8.  Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.

Authors:  Alexandra Abramsson; Per Lindblom; Christer Betsholtz
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall.

Authors:  Per Lindblom; Holger Gerhardt; Stefan Liebner; Alexandra Abramsson; Maria Enge; Mats Hellstrom; Gudrun Backstrom; Simon Fredriksson; Ulf Landegren; Henrik C Nystrom; Goran Bergstrom; Elisabetta Dejana; Arne Ostman; Per Lindahl; Christer Betsholtz
Journal:  Genes Dev       Date:  2003-08-01       Impact factor: 11.361

10.  Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival.

Authors:  D C Darland; L J Massingham; S R Smith; E Piek; M Saint-Geniez; P A D'Amore
Journal:  Dev Biol       Date:  2003-12-01       Impact factor: 3.582

View more
  93 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

2.  Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.

Authors:  Guanglei Zhuang; Xiumin Wu; Zhaoshi Jiang; Ian Kasman; Jenny Yao; Yinghui Guan; Jason Oeh; Zora Modrusan; Carlos Bais; Deepak Sampath; Napoleone Ferrara
Journal:  EMBO J       Date:  2012-07-06       Impact factor: 11.598

Review 3.  Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

Authors:  Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

4.  HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.

Authors:  Nilay Shah; Kideok Jin; Leigh-Ann Cruz; Sunju Park; Helen Sadik; Soonweng Cho; Chirayu Pankaj Goswami; Harikrishna Nakshatri; Rajnish Gupta; Howard Y Chang; Zhe Zhang; Ashley Cimino-Mathews; Leslie Cope; Christopher Umbricht; Saraswati Sukumar
Journal:  Cancer Res       Date:  2013-07-05       Impact factor: 12.701

Review 5.  Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis.

Authors:  Chenxi Hu; Xiaodong Jiang
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

6.  Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Authors:  Guillermo Garcia-Manero; Raoul Tibes; Tapan Kadia; Hagop Kantarjian; Martha Arellano; Emily A Knight; Hao Xiong; Qin Qin; Wijith Munasinghe; Lisa Roberts-Rapp; Peter Ansell; Daniel H Albert; Brian Oliver; Mark D McKee; Justin L Ricker; Hanna Jean Khoury
Journal:  Invest New Drugs       Date:  2015-05-02       Impact factor: 3.850

Review 7.  Role of platelet-derived growth factors in physiology and medicine.

Authors:  Johanna Andrae; Radiosa Gallini; Christer Betsholtz
Journal:  Genes Dev       Date:  2008-05-15       Impact factor: 11.361

8.  Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Authors:  Mohamed A Hamza; Jacob J Mandel; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Vinay K Puduvalli; John F DeGroot
Journal:  J Neurooncol       Date:  2014-05-07       Impact factor: 4.130

9.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.